TABLE 1.
Demographics of study population
| Demographics | Non‐VWD (n = 1005) | VWD (n = 454) | Low VWF:RCo cohort (n = 82) | Low VWF:RCo FU cohort (n = 37) |
|---|---|---|---|---|
| Race, n | ||||
| White | 833 (83%) | 390 (86%) | 66 (80%) | 31 (84%) |
| African American | 114 (11%) | 35 (8%) | 9 (11%) | 5 (14%) |
| Asian | 19 (2%) | 12 (3%) | 3 (4%) | 1 (3%) |
| Other or unknown | 39 (4%) | 17 (4%) | 4 (4%) | – |
| Ethnicity, n | ||||
| Latino | 116 (12%) | 57 (13%) | 11 (13%) | 7 (19%) |
| Non‐Latino | 882 (88%) | 389 (86%) | 71 (87%) | 30 (81%) |
| Unknown or not reported | 7 (1%) | 8 (2%) | – | |
| Sex (two unreported), n | ||||
| Female | 711 (71%) | 304 (67%) | 49 (60%) | 25 (68%) |
| Male | 294 (29%) | 148 (33%) | 33 (40%) | 12 (32%) |
| Adult vs pediatric, n | ||||
| Adult (>18 y) | 317 (32%) | 141 (31%) | 23 (28%) | 11 (30%) |
| Pediatric (<18 y) | 688 (68%) | 313 (69%) | 59 (72%) | 26 (70%) |
Note: Self‐reported race, ethnicity, sex, and distribution of adult (over 18 years of age; >18 year) and pediatric (under 18 years of age; <18 year) populations at time of enrollment in the non‐von Willebrand disease (non‐VWD) and VWD cohorts as well as subjects with a single low VWF ristocetin cofactor (VWF:Co) and those with available follow‐up (FU) testing.